Avalo Therapeutics, Inc.

Historical 13F Holders

Symbol
AVTX
CUSIP
05338F306
All holders as of
Q3 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 05338F306 since 12/18/2024, largest first.

Filer % of Class Filed
Commodore Capital LP 13G
9.9% 6/18/2026
Event 6/11/2026
TCG Crossover GP II, LLC 13G
7.9% 5/12/2026
Event 5/5/2026
Farallon Capital Management, L.L.C. 13G
7.4% 11/13/2026
Event 9/30/2026
Deep Track Capital, LP 13G/A
6.9% 8/14/2026
Event 6/30/2026
BlackRock, Inc. 13G 6.5% 7/27/2026
Event 6/30/2026
RA Capital Management, L.P. 13G/A
6.3% 8/14/2026
Event 6/30/2026
Caligan Partners LP 13G/A
5.9% 8/14/2026
Event 6/30/2026
Affinity Asset Advisors, LLC 13G/A
5.5% 8/13/2026
Event 6/30/2026
Trails Edge Capital Partners, LP 13G
5.2% 10/29/2026
Event 10/22/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (15)
State Street Corp 13G 4.8% 11/10/2026
Event 9/30/2026
Avoro Capital Advisors LLC 13G/A
4.4% 8/14/2026
Event 6/30/2026
Vanguard Group Inc 13G/A 4.4% 1/30/2026
Event 12/31/2025
Patrick J. Crutcher 13G/A 4.2% 8/27/2025
Event 8/6/2025
Ikarian Capital, LLC 13G/A
3.8% 11/14/2025
Event 9/30/2025
Nantahala Capital Management, LLC 13G/A
3.5% 8/14/2026
Event 6/30/2026
Logos Global Management LP 13G/A
3.2% 5/15/2026
Event 3/31/2026
Point72 Asset Management, L.P. 13G/A
3.0% 11/16/2026
Event 9/30/2026
SilverArc Capital Management, LLC 13G
2.8% 2/10/2026
Event 12/31/2025
Balyasny Asset Management L.P. 13G/A
2.4% 2/17/2026
Event 12/31/2025
OrbiMed Advisors LLC 13G/A 2.1% 5/15/2026
Event 3/31/2026
Biotechnology Value Fund L P 13G/A
1.7% 11/16/2026
Event 9/30/2026
FMR LLC 13G/A
0.9% 11/6/2026
Event 10/30/2026
Millennium Management LLC 13G/A
0% 7/6/2026
Event 6/30/2026
T. Rowe Price Investment Management, Inc. 13G/A 0% 8/14/2026
Event 6/30/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 149 71.6 M $1.10B
2026 Q2 127 70.8 M $1.31B
2026 Q1 101 31.1 M $464M
2025 Q4 85 19.9 M $361M
2025 Q3 66 15.3 M $195M
2025 Q2 37 7.84 M $39.1M
2025 Q1 35 8.26 M $66.1M
2024 Q4 34 7.53 M $56.0M
2024 Q3 30 6.66 M $63.2M
2024 Q2 22 771 k $9.62M
2024 Q1 19 87.5 k $1.90M
2023 Q4 13 23.0 k $209k